A Retrospective Chart Review to evaluate Safety and Tolerability in Ocrelizumab in Pediatric and Young-Adult Onset Multiple Sclerosis
Latest Information Update: 20 May 2020
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
Most Recent Events
- 20 May 2020 New trial record
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology